Cowen & Co. Keeps a Buy Rating on Molecular Templates Inc (MTEM)

By Ryan Adsit

In a report issued on March 29, Boris Peaker from Cowen & Co. maintained a Buy rating on Molecular Templates Inc (MTEMResearch Report). The company’s shares closed on Friday at $5.81.

According to TipRanks.com, Peaker is a 4-star analyst with an average return of 5.5% and a 42.4% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Mersana Therapeutics Inc, and CytomX Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Molecular Templates Inc.

See today’s analyst top recommended stocks >>

The company has a one-year high of $9.76 and a one-year low of $3.19. Currently, Molecular Templates Inc has an average volume of 63.67K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Molecular Templates, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics for the treatment of cancers and other serious diseases. The company was founded on August 1, 2017 and is headquartered in Austin, TX.